Cutaneous Adverse Reactions to TNF Alpha Blockers. Case Report and Literature Review

Alina Dumitru, Catalina I Dumitrascu, A. Dumitrache, Cristina Alexandru, Carmen Iorgus, A. Florescu, F. Bobircă, George Ciobotaru, I. Ancuta, A. Bobircă
{"title":"Cutaneous Adverse Reactions to TNF Alpha Blockers. Case Report and Literature Review","authors":"Alina Dumitru, Catalina I Dumitrascu, A. Dumitrache, Cristina Alexandru, Carmen Iorgus, A. Florescu, F. Bobircă, George Ciobotaru, I. Ancuta, A. Bobircă","doi":"10.31689/rmm.2023.30.1.37","DOIUrl":null,"url":null,"abstract":"Biological therapy is used in a wide range of medical settings. Adverse reactions to biological therapy can limit their widespread use, so early detection and treatment can adjust attempts to stop these molecules. TNF Alpha blockers may cause the following skin reactions in alpha patients: injection site reactions, infections, immune-mediated reactions (psoriasis, psoriasis, drug-induced lupus, vasculitis, hidradenitis, alopecia), allergic or neoplastic reactions. We present the case of a patient with RA who developed skin lesions during biological therapy and was diagnosed with drug induced lupus based on clinical elements, associated autoimmunity, and dermatological evaluation. The skin lesions were attributed to the interaction of three medications (biosimilar Etanercept, Leflunomide, and Isoniazid), all of which have been implicated in causing these side effects. The solutions that saved the patient were temporarily discontinuing the immunosuppressive medication and replacing it with a local corticoid, followed by the continuation of Etanercept in associated with Methotrexate, and the patient was able to continue the biological medication and obtain a favorable response to the treatment. In conclusion, skin changes caused by TNF Alpha inhibitors are common, but vary in severity, and do not warrant therapy interruption.","PeriodicalId":380281,"journal":{"name":"Medicina Moderna - Modern Medicine","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina Moderna - Modern Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31689/rmm.2023.30.1.37","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Biological therapy is used in a wide range of medical settings. Adverse reactions to biological therapy can limit their widespread use, so early detection and treatment can adjust attempts to stop these molecules. TNF Alpha blockers may cause the following skin reactions in alpha patients: injection site reactions, infections, immune-mediated reactions (psoriasis, psoriasis, drug-induced lupus, vasculitis, hidradenitis, alopecia), allergic or neoplastic reactions. We present the case of a patient with RA who developed skin lesions during biological therapy and was diagnosed with drug induced lupus based on clinical elements, associated autoimmunity, and dermatological evaluation. The skin lesions were attributed to the interaction of three medications (biosimilar Etanercept, Leflunomide, and Isoniazid), all of which have been implicated in causing these side effects. The solutions that saved the patient were temporarily discontinuing the immunosuppressive medication and replacing it with a local corticoid, followed by the continuation of Etanercept in associated with Methotrexate, and the patient was able to continue the biological medication and obtain a favorable response to the treatment. In conclusion, skin changes caused by TNF Alpha inhibitors are common, but vary in severity, and do not warrant therapy interruption.
TNF α阻滞剂的皮肤不良反应。病例报告及文献复习
生物疗法广泛应用于各种医疗环境中。生物疗法的不良反应会限制其广泛应用,因此早期检测和治疗可以调整阻止这些分子的尝试。TNF α阻滞剂可能引起α患者以下皮肤反应:注射部位反应、感染、免疫介导反应(牛皮癣、银屑病、药物性狼疮、血管炎、汗腺炎、脱发)、过敏或肿瘤反应。我们报告了一例RA患者,他在生物治疗期间出现皮肤病变,并根据临床因素、相关自身免疫和皮肤病学评估被诊断为药物性狼疮。皮肤损伤归因于三种药物(生物仿制药依那西普、来氟米特和异烟肼)的相互作用,所有这些药物都与引起这些副作用有关。挽救患者生命的方法是暂时停用免疫抑制药物并用局部皮质激素替代,随后继续使用依那西普联合甲氨蝶呤,患者能够继续使用生物药物并获得良好的治疗反应。总之,TNF α抑制剂引起的皮肤变化是常见的,但严重程度不同,不需要中断治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信